Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
9 evidence topics · 10 sources
Summary: anticipated place in treatment and care setting
Radical cystectomy is the guideline standard for BCG-unresponsive disease; the EAU 2026 guideline recommends offering it and recommends bladder preservation strategies, preferably within clinical trials, for patients who are not candidates for cystectomy or who decline it. BOND-003 enrolled participants who were medically unfit for cystectomy or who refused it, and the FDA draft guidance states that patients with BCG-unresponsive NMIBC “are unlikely to benefit from further therapy with BCG”. CG Oncology states that only approximately 6% of patients with NMIBC elect cystectomy, and another publication reports real-world rates of radical cystectomy for NMIBC below 20%.
The anticipated first use is in BCG-unresponsive high-risk NMIBC with carcinoma in situ, with or without papillary tumors. In its PIVOT-006 topline release, CG Oncology stated that, based on FDA feedback, the initial BLA will be broadened to include both carcinoma in situ and high-grade papillary-only disease, with completion anticipated in March 2027. Cretostimogene would enter a setting in which the FDA has approved pembrolizumab, nadofaragene firadenovec, nogapendekin alfa inbakicept-pmln with BCG, and TAR-200 for high-risk, BCG-unresponsive NMIBC with CIS ± Ta/T1.
The expected care setting is the urology office. BOND-003 Cohort C was run at 41 community and academic centres. Cretostimogene is instilled through a soft catheter without anesthesia or operating room time, and the company states that a medical assistant or nurse can prepare and administer it. The product is handled under biosafety level 2 precautions, described as “BSL-2 like BCG”, with protective equipment during preparation and administration. CG Oncology describes a field organization directed at community and academic urology networks.
Guideline position of radical cystectomy and bladder preservation
Population that declines or is unfit for cystectomy
Company positioning as a bladder-sparing therapy after BCG
Anticipated initial indication including papillary-only disease
Care setting: in-office intravesical instillation without anesthesia
“BOND-003 Cohort C is a single-arm, international, phase 3 study done in 41 centres (community practices and academic centres) located in North America, Asia, and Australia.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote